Genetic determinants of variable anti-diabetic therapy responses across diverse populations with type 2 diabetes mellitus: a systematic review and meta-analysis
Authors' conclusion
Glycemic responses to anti-diabetic drugs vary across ethnic groups and are influenced by genetic variants. These findings support the need for personalised, genotype-guided therapy to improve glycemic control. Further research is necessary to explore broader drug classes and demographic factors.
Study context
- Population
- Populations with T2D across ethnic groups36 studies
- Comparison
- Gene polymorphisms and glycaemic response to anti-diabetic therapy across ethnic populations
- Outcome
- Glycaemic response by genetic variant and ethnic population
Methodological detailsPooled odds ratios (ORs) with 95 % CI for binary and pooled standardized mean differences (SMDs) with 95 % CI for continuous glycaemic outcomes; heterogeneity by I2 and Cochran Q tests
- Pooled ORs with 95 % CI for binary and pooled SMDs with 95 % CI for continuous glycaemic outcomes; heterogeneity by I2 and Cochran Q tests
Pooled result
As reported in the abstract
- Significant associations between improved glycaemic response and SLC22A1 rs622342, SLC47A2 rs12943590, TCF7L2 rs7903146, SLC22A1 rs12208357 and ABCC8 rs757110
- p < 0.05
- Significant HbA1c reductions with biguanide monotherapy in Arabian, Indian, Mestizo and Persian populations
- p < 0.05
Original publication
Genetic determinants of variable anti-diabetic therapy responses across diverse populations with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract. Published 24 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →